English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/76842
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorYeramian, A.-
dc.contributor.authorMoreno-Bueno, Gema-
dc.contributor.authorPalacios Calvo, José-
dc.contributor.authorMatías-Guiu, Xavier-
dc.identifierissn: 0950-9232-
dc.identifiere-issn: 1476-5594-
dc.identifier.citationOncogene 32(4): 403-413 (2013)-
dc.description.abstractIn the western world, endometrial carcinoma (EC) is the most common cancer of the female genital tract. The annual incidence has been estimated at 10-20 per 100 000 women. Two clinicopathological variants are recognized: the estrogen related (type I, endometrioid) and the non-estrogen related (type II, non-endometrioid).The clinicopathological differences are paralleled by specific genetic alterations, with type I showing microsatellite instability and mutations in phosphatase and tensin homologue deleted on chromosome 10, PIK3CA, K-RAS and CTNNB1 (β-catenin), and type II exhibiting TP53 mutations and chromosomal instability. Some non-endometrioid carcinomas probably arise from pre-existing endometrioid carcinomas as a result of tumor progression and, not surprisingly, some tumors exhibit combined or mixed features at the clinical, pathological and molecular levels. In EC, apoptosis resistance may have a role in tumor progression. Understanding pathogenesis at the molecular level is essential in identifying biomarkers for successful targeted therapies. In this review, the genetic changes of endometrial carcinogenesis are discussed in the light of the morphological features of the tumors and their precursors. © 2013 Macmillan Publishers Limited.-
dc.description.sponsorshipThis work was supported by grants from FIS PI100922, Fundación Mutua Madrileña AP75732010, FIS PI080410, 2009SGR794, RD06/0020/1034, RD06/0020/0013, RD06/ 0020/0058, RD06/0020/0015, Fundación Asociación Española contra el Cáncer and programa de intensificación de la investigación, Instituto Carlos III. AY holds a postdoctoral fellowship from Programa Juan de la Cierva, Ministerio de Ciencia e Innovación (JCI-2008-1969).-
dc.publisherNature Publishing Group-
dc.titleEndometrial carcinoma: Molecular alterations involved in tumor development and progression-
dc.description.versionPeer Reviewed-
dc.contributor.funderMinisterio de Ciencia e Innovación (España)-
dc.contributor.funderFundación Mutua Madrileña-
dc.contributor.funderAsociación Española Contra el Cáncer-
dc.contributor.funderInstituto de Salud Carlos III-
Appears in Collections:(IIBM) Artículos
(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.